- In August 2024, Thermo Fisher Scientific Inc. received three R&D 100 Awards, including a gold award for the Orbitrap Astral Mass Spectrometer, a major advancement in mass spectrometry. This instrument improves proteome coverage and throughput, facilitating breakthroughs in precision medicine. The Gibco CTS Detachable Dynabeads platform also gained recognition for its innovative active release mechanism, enhancing efficiency in cell therapy manufacturing. These accolades underscore Thermo Fisher's dedication to scientific innovation
- In August 2024, Thermo Fisher Scientific Inc. completed its acquisition of Olink Holding AB for approximately USD 3.1 billion, integrating Olink into its Life Sciences Solutions segment. This acquisition enhances Thermo Fisher's capabilities in proteomics, vital for advancing precision medicine. The tender offer accepted all validly tendered shares at $26.00 each, resulting in Thermo Fisher owning about 98.2% of Olink's outstanding shares. The subsequent offering period will expire at 5:00 p.m. New York time on July 16, 2024
- In July 2024, Thermo Fisher Scientific Inc. opened its first electron microscopy demo center, or NanoPort, in Taiwan to support semiconductor innovation and materials R&D. Located in a key semiconductor manufacturing hub, the facility will provide access to advanced analytical instruments and expert guidance, helping customers accelerate research and reduce time-to-market. This new center joins five other NanoPorts globally, reinforcing Thermo Fisher's commitment to advancing science and technology.
- In June 2024, Thermo Fisher Scientific Inc. introduced the Stellar mass spectrometer, enhancing clinical research and precision medicine. With fast throughput and high sensitivity, it enables efficient verification of proteins and metabolites, achieving ten times the quantitative sensitivity of traditional methods. This innovation accelerates study completion and improves productivity, supporting the development of personalized therapies
